(Oregon Health & Science University) Today the New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec's 2001 FDA approval, fewer than one in three CML patients survived five years past diagnosis.
############
Story Source: Materials provided by Scienmag
